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ArrhythmiaAbstract Background: Although pneumonia is a leading cause of death, little consideration has
been given to understanding the contributors to this mortality. Previous studies have suggested
an increased mortality in pneumonia patients who develop cardiac complications. The aim of this
study was to examine the risk factors and outcome of cardiac complications in admitted patients
with community-acquired pneumonia.
Patients and methods: This study included 130 patients hospitalized with a primary diagnosis of
community-acquired pneumonia. All patients were subjected to complete medical history, general
and local chest examination, Laboratory investigations (complete blood count, renal and hepatic
function tests, serum electrolytes, blood sugar, arterial blood gas analysis, CRP, procalcitonin,
BNP, cardiac enzymes, blood and sputum Gram stain and culture, sputum PCR for Mycoplasma
pneumoniae, Legionella pneumophila, Coxiella burnetii, and Chlamydophila species, urine antigen
testing for S. pneumoniae and L. pneumophila, pharyngeal swabs for viral PCR.), radiological
investigations, electrocardiographic studies (ECG) and echocardiography.
Results: Among the studied 130 patients, 32 patients (24.6%) had cardiac complications [new or
worsening heart failure in16 patients (12.3%), arrhythmias in 12 patients (9.2%), and acute myocar-
dial infarction in 4 patients (3.1%)]. In comparing patients who developed cardiac complications
with those who did not they had a signiﬁcantly higher age (mean ± SD 69 ± 17.3 versus
49 ± 19.1, p< 0.05), included a signiﬁcantly higher percentage of patients with preexisting cardio-
vascular diseases (40.6% versus 5.1%, p< 0.05), had a signiﬁcantly higher pneumonia severity
index (PSI) (mean ± SD 130 ± 27 versus 73 ± 29, p< 0.05), a signiﬁcantly longer hospital stay
(mean ± SD 22 ± 7.1 versus 9 ± 4.3, P< 0.05) and a signiﬁcantly higher mortality (21.8% versus
6.1%, P< 0.05).
Conclusions: Cardiac complications are common in the admitted patients with pneumonia and
they are associated with increased pneumonia severity and increased cardiovascular risk, theserculosis.
634 R. Eman Shebl, M.S. Hamoudacomplications adds to the risk of mortality, so optimal management of these events may reduce the
burden of death associated with this infection.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pneumonia is widely recognized as a major cause of morbidity
and mortality. Clinically, pneumonia exhibits an extreme vari-
ety in the severity of presentation, from almost asymptomatic
disease on one side to a fulminant event on the other [1].
Clinical risk scores have been developed for adult patients
with pneumonia and are widely used to identify high risk
patients in need of intensive treatment and careful monitoring,
and low risk patients who may be suitable for out-patient
treatment. These scores use clinical indicators from multiple
organ systems, acknowledging the importance of systemic
illness severity, advanced age, and reduced physiological
reserve in determining mortality from pneumonia. For exam-
ple, only four of the 20 measures in the pneumonia severity
index (PSI) and one of ﬁve components of the widely used
CURB 65 score (Confusion, Urea, and Respiratory rate,
Blood pressure, and age P65 years) are direct measures of
respiratory function [2]. Mortensen et al. [3] reported that
about half of deaths in patients with CAP was attributable
to worsening of a pre-existing condition.
Recent studies indicate that cardiac complications are com-
mon in patients with community-acquired pneumonia [4–7].
However, the frequency of these complications in unselected
CAP patients, the contribution of speciﬁc cardiac events to this
burden, the timing of these complications in the course of
CAP, the factors associated with their development, and their
association with the short-term mortality of this infection
remain unclear.
Acute bacterial pneumonia stresses the heart by increasing
myocardial oxygen demand at a time when oxygenation is
compromised by a ventilation–perfusion mismatch.
Pneumonia also raises circulating levels of inﬂammatory
cytokines, which promote thrombogenesis and suppress ven-
tricular function. Taken together, these pathophysiologic
events might be expected to lead to major, acute cardiac
events, such as myocardial infarction (MI), arrhythmia,
and/or congestive heart failure (CHF) [8–10].
The aim of this study was to examine the risk factors and
outcome of cardiac complications in admitted patients with
community-acquired pneumonia as this might help to assess
the risk of death and institute the appropriate level of care.
Patients and methods
This clinical study was carried out on 130 patients (68 males
and 62 females with a mean age of 59 ± 19.3) hospitalized
with a primary diagnosis of community-acquired Pneumonia
(CAP) in the period between July 2012 and September 2014
after taking informed consent. Patients with presence of an
alternative diagnosis that likely explained the pulmonary
symptoms and X-ray inﬁltrate (e.g., lung carcinoma,
pulmonary edema, or pulmonary embolus) were excluded.All patients were subjected to:
– Complete medical history.
– General and local chest examination.
– Laboratory investigations: complete blood count, renal and
hepatic function tests, serum electrolytes, blood sugar,
arterial blood gas analysis, CRP, procalcitonin (Kryptor
PCT, Brahms, Hennigsdorf, Germany), brain natriuretic
peptide (NT-BNP) (Roche Diagnostics Corp.,
Indianapolis, IN, USA) and serum troponin I (cTnI) con-
centration using a Siemens Advia Centaur TnI-Ultra
Assay (serum cTnI concentration was considered raised if
it was P0.04 lg L).
– Microbial etiology: At least two sets of separate blood and
sputum samples of each patient were Gram stained and
cultured. Moreover, sputum samples were analyzed with
TaqMan real-time polymerase chain reactions (PCRs) in
order to detect DNA of Mycoplasma pneumoniae,
Legionella pneumophila, Coxiella burnetii, and Chlamydophila
species. Antigen testing of S. pneumoniae and L. pneumophila
was performed in urine samples. Furthermore, pharyngeal
swabs were taken for viral culture and viral PCR [11].
– Radiological investigations (plain x ray and computed
tomography on the chest).
– Electrocardiographic studies (ECG).
– Echocardiography.
Deﬁnitions
Pneumonia was deﬁned as the presence of a new pulmonary
inﬁltrate on a chest radiograph at the time of hospitalization
associated with one or more of the following: (1) new or
increased cough with/without sputum production; (2) fever
(P 37.8 C) or hypothermia (6 35.6 C); or (3) abnormal
white blood cell count (either leukocytosis or leukopenia), or
C-reactive protein values above the local upper limit [12].
Severity of pneumonia: on admission to the hospital,
patients were assessed using the Pneumonia Severity Index
(PSI), a validated prediction rule for 30-day mortality in
patients with CAP [2].
Acute myocardial infarction (AMI) The diagnosis of AMI
According to the WHO criteria as revised in 2000 [13], a car-
diac troponin rise accompanied by either typical symptoms
or ischemic ECG changes (ST-segment elevation 0.1 mV or
greater in 2 or more contiguous leads, ST-segment depression,
T-wave abnormality, and development of pathological Q
waves).
New or worsening heart failure, i.e., the presence of clinical
signs of new or worsening pulmonary edema or acute conges-
tive heart failure detected by the managing physician.
New arrhythmias ECG monitor, or Holter monitor
of newly recognized atrial ﬁbrillation, atrial ﬂutter,
Table 2 Cardiac Complications of the studied patients.
Cardiac complications No. of patients (%)
No cardiac complications 98 (75.4)
Cardiac complications 32 (24.6)
New or worsening heart failure 16 (12.3)
New arrhythmias 12 (9.2)
Acute myocardial infarction 4 (3.1)












12 (37.5) 7 (7.1) <0.05
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PSI 130 ± 27 73 ± 29 <0.05
PSI: pneumonia severity index.











Community-acquired pneumonia with cardiac complications 635supraventricular tachycardia, multifocal atrial tachycardia,
ventricular tachycardia or ventricular ﬁbrillation.
Statistical analysis
Results are given as numbers, percentage or mean ± SD.
Demographic and physiologic characteristics of the two
groups were compared with use of Student’s t-test for continu-
ous data and chi-square test for categorical data. The SPSS
version 19 software package (SPSS, Chicago) was used for
all analyses. P< 0.05 was considered as statistically
signiﬁcant.
Results
Demographic characteristics and comorbidities in the studied
patients who developed and who did not develop cardiac
complications are presented in Table 1. Patients who
developed cardiac complications had a signiﬁcantly higher
age (mean ± SD 69 ± 17.3 vs. 49 ± 19.1, P< 0.05) and
included a signiﬁcantly higher percentage of patients with
preexisting cardiovascular diseases (history of heart failure,
prior cardiac arrhythmias, previously diagnosed coronary
artery disease, hyperlipidemia or arterial hypertension)
(40.6% vs. 5.1%, P< 0.05).
Table 2 shows distribution of cardiac complications among
the studied 130 patients in which 32 patients (24.6%) had car-
diac complications. New or worsening heart failure happened
in 16 patients (12.3%). Arrhythmias happened in 12 patients
(9.2%). Finally, MI was documented in 4 patients (3.1%).
In this study patients who developed cardiac complications
compared with those who did not develop cardiac com-
plications had a signiﬁcantly higher PSI (130 ± 27 vs.
73 ± 29, P< 0.05), higher percentage of patients with altered
mental status, Systolic blood pressure <90 mmHg, pulse
P125 bpm, Respiratory rate P30 breaths/min (Table 3).
As regard to laboratory characteristics of the studied
patients, the percentage of patients who had blood pH
<7.35, blood urea nitrogen P30 mg/dL, sodium











Age (mean ± SD,
y)
69 ± 17.3 49 ± 19.1 <0.05
Sex (male/female) 17/15 51/47 >0.05





13 (40.6) 5 (5.1) <0.05
Diabetes 7 (21.9) 19 (19.4) >0.05
COPD 6 (18.6) 17 (17.3) >0.05
Cerebrovascular
disease
3 (9.3) 10 (8.4) >0.05
Chronic renal
disease
3 (9.4) 8 (8.1) >0.05
Hematocrit
<30%




20 (62.5) 22 (22.4) <0.05
Sodium
<130 mmol/L
12 (37.5) 7 (7.1) <0.05





25 (78.1) 31 (31.6) <0.05
Glucose
P250 mg/dl
10 (31.2) 6 (6.1) <0.05O2 sat <90 mmHg was signiﬁcantly higher in patients who
developed cardiac complications than those without cardiac
complications (Table 4).
Table 5 shows that patients with cardiac complications had
signiﬁcantly higher procalcitonin levels than patients without
cardiac complications (mean ± SD 20 ± 3.2 vs. 5.2 ± 1.3)
Table 5 Initial inﬂammatory and myocardial injury markers

























15 (46.7) 11 (11.2) <0.05
BNP: brain natriuretic peptide.












Lobar pattern 6 (18.8) 53 (54.1) <0.05
Interstitial pattern 18 (56.3) 24 (24.5) <0.05
Segmental pattern 4 (12.5) 11 (11.2) >0.05
Bronchopneumonia 4 (12.5) 10 (10.2) >0.05
Presence of pleural
eﬀusion
12 (37.5) 12 (12.2) <0.05













17 (53.1) 7 (7.1) <0.05
Acute renal
failure
13 (40.6) 4 (4.1) <0.05
Hospital stay
in days
22 ± 7.1 9 ± 4.3 <0.05
Mortality 7 (21.8%) 6 (6.1) <0.05
MV: mechanical ventilation.
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increased NT-BNP and increased troponin I (59.3% vs.
12.2% and 46.7% vs. 11.2%, respectively).
In the present study, as regard to radiology (Table 6)
interstitial pattern of pneumonia and the presence of pleural
effusion were signiﬁcantly common in patients who developed
cardiac complications compared to patients without cardiaccomplications (56.3% vs. 24.5% and 37.5% vs. 12.2%,
P< 0.05).
Table 7 shows the outcome of the studied patients during
the admission period in which patients who developed cardiac
complications compared with those who did not, the percent-
age of patients who received mechanical ventilation was 46.9%
vs. 6.1%, P< 0.05, those who received inotropes and
vasopressors 53.1 vs. 7.1%, P< 0.05, occurrence of acute
renal failure in 40.6% vs. 4.1%, hospital stay 22 ± 7.1 vs.
9 ± 4.3, P< 0.05 and mortality 21.8% vs. 6.1%, P< 0.05.
Discussion
Although CAP is a leading cause of death, little consideration
has been given to understanding the contributors to this mor-
tality. Recent studies indicate that cardiac complications are
common in patients with community-acquired pneumonia
[4–7]. However, the frequency of these complications in CAP
patients, the contribution of speciﬁc cardiac events to this bur-
den, the timing of these complications in the course of CAP,
the factors associated with their development, and their
association with the short-term mortality of this infection
remains unclear. This study was carried out to examine the risk
factors and outcome of cardiac complications in admitted
patients with community-acquired pneumonia as this might
help to assess risk of death and institute the appropriate level
of care.
In this study 32 patients of 130 (24.6%) admitted patients
with primary diagnosis of pneumonia, had cardiac com-
plications: new or worsening heart failure in 16 patients
(12.3%), new arrhythmias in 12 patients (9.2%) and AMI in
4 patients (3.1%). This ﬁnding agrees with Carlos et al. [5]
who reported that major cardiac complications occurred in a
substantial proportion (17.7%) of patients with community-
acquired pneumonia, including incident heart failure, acute
coronary syndromes, and arrhythmias.
Epidemiological studies have demonstrated that respiratory
tract infections are associated with an increased risk for the
development of acute myocardial infarction [14,9]. One recent
study [15] that speciﬁcally sought non cardiac conditions in
patients who had acute MI found that 7.2% of these patients
had pneumonia; the authors emphasized, the tendency of
admitting physicians to conﬁne their assessment to a single
diagnosis.
Musher et al. [16] reported that an associated AMI was
found in 12 (7%) of 170 patients with pneumococcal pneumo-
nia at time of hospital admission. Ramirez et al. [17] reported
an incidence of myocardial infarction at the time of hospital
admission of 5.8% in 500 patients hospitalized with
community-acquired pneumonia. Corrales et al. [5] reported
an incidence of myocardial infarction of 10.7% in 206 patients
hospitalized with pneumonia. This incidence was measured
during the ﬁrst 15 days after hospital admission. The incidence
of myocardial infarction occurring during hospitalization due
to pneumonia in the study of Perry et al. [18] was 1.4%.
Differences in these incidences may be explained by differences
in the studied patient populations.
Several mechanisms, can account for the development of
MI in patients with CAP. Hypoxemia decreases myocardial
oxygen delivery and raises pulmonary arterial pressure and
right ventricular afterload. Tachycardia increases myocardial
Community-acquired pneumonia with cardiac complications 637oxygen needs and shortens the diastole (when coronary perfu-
sion occurs). Acute infections can promote inﬂammatory
activity within coronary athero-sclerotic plaques and induce
prothrombotic changes in the blood and endothelium, result-
ing in plaque instability and facilitating coronary thrombosis.
Preexisting coronary artery disease that is insufﬁcient to
produce myocardial ischemia under baseline conditions can
also result in signiﬁcant ischemia in the face of increased
myocardial oxygen demand [16].
In the study of Perry et al. [18] the incidence was 19.2% for
new or repeat congestive heart failure and 6.4% for cardiac
arrhythmias in the studied patients with pneumonia. Musher
et al. [16] reported that the incidence of new-onset or worsen-
ing congestive heart failure for 14% of their sample and an
incidence of new-onset arrhythmia (including atrial ﬂutter,
atrial ﬁbrillation, and ventricular tachycardia of 5.8%. These
incidences were measured at the time of admission for pneu-
monia. These ﬁndings agree with the present study which
showed that new-onset or worsening congestive heart failure
occurred in 12.3% and new-onset arrhythmia in 9.2% of the
studied patients with community acquired pneumonia.
The ability of pneumonia to cause acute abnormalities in
the cardiac conduction system has been recognized since the
early 20th century and consistently conﬁrmed thereafter [19].
The occurrence of CHF in pneumonia may be explained by
many factors including increased myocardial demand for
oxygen, lowered blood oxygen levels, and suppression of
ventricular function by elevated levels of cytokines [20].
Biventricular impairment of intrinsic myocardial contractility,
which may be present in 50% of patients with severe sepsis or
septic shock [13].
This study identiﬁes speciﬁc factors associated with the
occurrence of cardiac complications in the admitted patients
with pneumonia, these factors include higher age, presence of
underlying cardiovascular diseases (previously diagnosed coro-
nary artery disease, Congestive heart failure, arrhythmias and
hypertension), and more severe pneumonia at presentation
(respiratory rate P30 breaths per minute, blood pH <7.35,
blood urea nitrogen P30 mg/dL, sodium <130 mmol/L,
hematocrit <30%, which agrees with previous studies [5,7].
Elevated levels of B-type natriuretic peptides (markers of
cardiac failure due to pressure or volume overload) are reported
to be common in community-acquired lower respiratory tract
infections and are associated with a higher risk of adverse
outcome [8,9]. In this study elevated brain natriuretic peptide
was present in 59.3% of patients with cardiac complications
and 12.2% of patients without cardiac complications.
Elevated levels of cardiac troponins (indicating myocardial
injury) have also been linked to increased disease severity in
community-acquired pneumonia [10,21]. The present study
showed that increased troponin I was present in 46.7% of
patients with cardiac complications and 11.2% of patients
without cardiac complications.
In this study there was a signiﬁcant increase in hospital stay
and mortality in the studied pneumonia patients with cardiac
complications. As 7 of 32 (21.8%) patients who had cardiac
events died, compared with 6 of 98 (6.1%) patients who did
not experience cardiac events. This ﬁnding agrees with the
study of Corrales et al. [5], in which the development of cardiac
complications was associated with a substantial increase (60%)
in the risk of death at 30 days, even after adjustment for
patients’ PSI score which is considered the mostcomprehensive and sensitive tool for predicting short-term
mortality on presentation with CAP [2,22].
Conclusion: cardiac complications are common in the
admitted patients with primary diagnosis of pneumonia and
they are associated with increased pneumonia severity and
increased cardiovascular risk, these complications add to the
risk of mortality, so the prevention and optimal management
of these events may signiﬁcantly reduce the burden of death
associated with this infection.Conﬂict of interest
None.References
[1] M. Woodhead, F. Blasi, S. Ewig, et al, Joint Taskforce of the
European Respiratory Society and European Society for
Clinical Microbiology and Infectious Diseases: guidelines for
the management of adult lower respiratory tract infections, Clin.
Microbiol. Infect. 17 (Suppl. 6) (2011) E1–E59.
[2] M.J. Fine, T.E. Auble, D.M. Yealy, et al, A prediction rule to
identify low-risk patients with community-acquired pneumonia,
N. Engl. J. Med. 336 (1997) 243–250.
[3] E.M. Mortensen, C.M. Coley, D.E. Singer, et al, Causes of
death for patients with community-acquired pneumonia: results
from the Pneumonia Patient Outcomes Research Team cohort
study, Arch. Intern. Med. 162 (2002) 1059–1064.
[4] P. Mandal, J.D. Chalmers, G. Choudhury, et al, Vascular
complications are associated with poor outcome in community-
acquired pneumonia, QJM 104 (2011) 489–495.
[5] V.F. Corrales-Medina, D.M. Musher, G.A. Wells, et al,
Cardiac complications in patients with community-acquired
pneumonia: incidence, timing, risk factors, and association with
short-term mortality, Circulation 125 (2012) 773–781.
[6] A. Singanayagam, D.H.J. Elder, J.D. Chalmers, Is community-
acquired pneumonia an independent risk factor for
cardiovascular disease?, Eur Respir. J. 39 (2012) 187–196.
[7] D. Viasus, C. Garcia-Vidal, F. Manresa, et al, Risk
stratiﬁcation and prognosis of acute cardiac events in
hospitalized adults with community-acquired pneumonia,
J. Infect. (2012), http://dx.doi.org/10.1016/j.jinf.09.003.
[8] C. Goritsas, M. Fasoulaki, N.P. Paissios, et al, Brain natriuretic
peptide plasma levels as a marker of prognosis in patients with
community-acquired infection, Eur. J. Emerg. Med. 17 (2010)
293–295.
[9] C.R. Meier, S.S. Jick, L.E. Derby, et al, Acute respiratory tract
infections and risk of ﬁrst-time acute myocardial infarction,
Lancet 351 (1998) 1467–1471.
[10] L. Smeeth, S.L. Thomas, A.J. Hall, et al, Risk of myocardial
infarction and stroke after acute infection or vaccination, N.
Engl. J. Med. 351 (2004) 2611–2618.
[11] H. Endeman et al, Clinical features predicting failure of
pathogen identiﬁcation in patients with community acquired
pneumonia, Scand. J. Infect. Dis. 40 (2008) 715–720.
[12] L.A. Mandell, R.J. Wunderink, A. Anzueto, et al, Infectious
Diseases Society of America/American Thoracic Society
consensus guidelines on the management of community-
acquired pneumonia in adults, Clin. Infect. Dis. 44 (2007)
S27–S72.
[13] J.S. Alpert, K. Thygesen, E. Antman, et al, Myocardial
infarction redeﬁned: a consensus document of the Joint
European Society of Cardiology/American College of
Cardiology committee for the redeﬁnition of myocardial
infarction, J. Am. Coll. Cardiol. 36 (2000) 959–969.
638 R. Eman Shebl, M.S. Hamouda[14] F. Blasi, R. Cosentini, R. Raccanelli, et al, A possible
association of Chlamydia pneumoniae infection and acute
myocardial infarction in patients younger than 65 years of age,
Chest 112 (1997) 309–312.
[15] V.F. Corrales-Medina, M. Madjid, D.M. Musher, Role of acute
infection in triggering acute coronary syndromes, Lancet Infect.
Dis. 10 (2010) 83–92.
[16] D.M. Musher, A.M. Rueda, A.S. Kaka, et al, The association
between pneumococcal pneumonia and acute cardiac events,
Clin. Infect. Dis. 45 (2007) 158–165.
[17] J. Ramirez, S. Aliberti, M. Mirsaeidi, P. Peyrani, et al,
Acute myocardial infarction in hospitalized patients with
community-acquired pneumonia, Clin. Infect. Dis. 47 (2008)
182–187.
[18] T.W. Perry, M.J. Pugh, G.W. Waterer, et al, Incidence of
cardiovascular events after hospital admission for pneumonia,
Am. J. Med. 124 (2011) 244–251.[19] M. Maeder, T. Fehr, P. Rickli, H. Ammann, Sepsis-associated
myocardial dysfunction: diagnostic and prognostic impact of
cardiac troponins and natriuretic peptides, Chest 129 (2006)
1349–1366.
[20] A. Kumar, V. Thota, L. Dee, et al, Tumor necrosis factor alpha
interleukin 1 beta are responsible for in vitro myocardial cell
depression induced by human septic shock serum, J. Exp. Med.
183 (1996) 949–958.
[21] T. Reynolds, R. Rahman-West, P. Collinson, et al, Serial
troponin I sampling in a large ICU cohort: increased troponin
I concentrations are common in critically ill patients and are
associated with poor outcome, Intensive Care Med. 35 (2009)
S281.
[22] W.S. Lim, M.M. Van der Eerden, R. Laing, et al, Deﬁning
community acquired pneumonia severity on presentation to
hospital: an international derivation and validation study,
Thorax 58 (2003) 377–382.
